Ben and Sam discuss Jhonny Peralta’s contract with the Cardinals, and whose responsibility it should be to publish PED users.
Going public won’t help Alex Rodriguez win his case.
What’s the most likely outcome of A-Rod’s appeal?
Ben and Sam talk about whether teams should step up advance scouting in the upper minors, then discuss the difference (or lack thereof) between the PEDs MLB bans and the procedures it allows.
A plea to stop the speculation from a player who’s heard more than his fair share.
What Xander Bogaerts’ promotion means for the Red Sox and for the rise of young talent in the post-PED era.
The real danger Biogenesis revealed and the false threat that we shouldn’t make this about.
Ben and Sam answer listener emails about the consequences of abolishing the trade deadline, baseball’s war on PEDs, time traveling front offices, and more.
Why Ryan Braun’s suspension isn’t bad news, and other reflections on the latest in the Biogenesis saga.
Ben and Sam talk about whether it’s ever fair to suspect that a player is taking PEDs, then discuss Ruben Amaro’s comments about public prospect rankings.
Ben and Sam discuss the latest developments in the Biogenesis saga.
Some 20 players could be suspended for ties to Biogenesis, as the league seeks testimony from Tony Bosch in a case that could have far-reaching financial implications.
Former fringe major leaguer Eric Knott dishes on his difficult decisions about PED use during his time as a professional player.
Ben and Sam answer listener emails about how much steroids help, the best farm systems in baseball, and how they’d try to negotiate a hypothetical trade.
Character assassination, speculation, a commitment to process… ah, it has to be Hall of Fame season.
How much did Melky Cabrera’s suspension affect San Francisco’s odds of appearing in October?